A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Clinical trial NCT03946670 · TERMINATED
Trial details
- NCT number
- NCT03946670
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-04
- Primary completion
- 2022-04-26
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.